English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Autoimmune hemolytic anemia (AIHA) presenting concomitantly with multiple myeloma (MM) has been reported in a limited number of cases. Here we report a case of MM initially presenting as AIHA that was subsequently treated with bortezomib (Velcade®, formerly PS-341). Initial treatment of AIHA became refractory to corticosteroids, however subsequent diagnosis and treatment of MM with bortezomib yielded significant clinical responses to both the MM and the relapsed AIHA. Bortezomib is currently approved for treatment of MM and mantle cell lymphoma, but may have potential to treat other hematologic and malignant disorders.

clinical reviews and cases

Multiple Myeloma Presenting as Autoimmune Hemolytic Anemia: Bortezomib as Potential Therapy for Autoimmune Hemolytic Anemia Refractory to Standard Corticosteroid Therapy